Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.50 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.49 |
| ▸ | RRM1 | P23921 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13810574 | 0.94 | CA1 (0.53) | EPHX1CA1CNR1GNAI3GNAO1 | |
| SCHEMBL28052076 | 0.92 | GNAI3 (0.58) | EPHX1CA1CNR1GNAI3GNAO1 | |
| SCHEMBL28285001 | 0.92 | GNAI3 (0.58) | EPHX1CA1CNR1GNAI3GNAO1 | |
| SCHEMBL14874696 | 0.92 | GNAI3 (0.58) | EPHX1CA1CNR1GNAI3GNAO1 | |
| SCHEMBL11181600 | 0.92 | GNAI3 (0.54) | EPHX1CA1CNR1GNAI3GNAO1 | |
| SCHEMBL28100557 | 0.92 | GNAI3 (0.58) | EPHX1CA1CNR1GNAI3GNAO1 | |
| SCHEMBL28052266 | 0.92 | GNAI3 (0.58) | EPHX1CA1CNR1GNAI3GNAO1 | |
| SCHEMBL9462535 | 0.92 | DPP7 (0.52) | EPHX1CA1CNR1GNAI3GNAO1 | |
| SCHEMBL28328772 | 0.89 | DPP7 (0.62) | EPHX1CNR1GNAI3GNAO1GNAI1 | |
| SCHEMBL21467378 | 0.86 | DPP7 (0.65) | EPHX1CA1CNR1GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10688216-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-9675605-B2 | Substituted naphthyridine and quinoline compounds as MAO inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10688216-B2 | Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices | PLOD3, LIG3, PLOD2 | EPHX1 320/4885CA1 2242/4885CNR1 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.